Immunovia - Discover and develop tools for early diagnosis of cancers

March 29, 2021
Immunovia reports historical breakthrough in early detection of pancreatic cancer in high risk groups

IMMray™ PanCan-d blood test detects early stage pancreatic cancers with 98% specificity and 85% sensitivity in large blinded clinical validation study of familial hereditary risk group cohorts in USA

IMMray™ PanCan-d shows improved test performance and demonstrates specificity / sensitivity of 92% / 80% in detecting early stage pancreatic cancers in clinical study with high risk symptomatic patient cohorts

LATEST WEBINAR
45 min

Press releases

June 30, 2021

Immunovia, Inc. Receives Certificate of Registration – Clinical Laboratory Licensure Still Pending

May 28, 2021

CEO Patrik Dahlen purchases Immunovia shares

May 27, 2021

Immunovia to Host a Key Opinion Leader Event on the Clinical Use of IMMray™ PanCan-d

Financial reports

April 2021

Immunovia AB published the company’s Interim Report January–March 2021 on Wednesday, April 28, 2021, at 4.00 p.m. CET.

Immunovia Interim Report Jan–March 2021 (PDF in English)

Immunovia Interim Report Jan–March 2021 (PDF in Swedish)

Financial reports

Calendar

19 August, 2021

Interim Report Jan-June 2021

Place: Immunovias website

1 September, 2021

Lab & Diagnostics of the Future – Swedish Lab Days

Place: Stockholm, Sweden

3 September, 2021

Nordic symposium Pancreas cancer: Improving Diagnosis, Treatment and Care

Place: Herlev, Copenhagen, Denmark